Vascular endothelial growth factor receptor 2 (VEGFR2) is one of the main targets for anti-angiogenic tumor therapy, as its activation with VEGFA induces proliferation, migration, and angiogenesis in solid tumors [49]. The gene discussed is KDR; the disease is neoplasm.